Covid19
Conditions
Keywords
AIDS, HIV, HBV, HCV, Stroke, Metabolic dissorder, Stress
Brief summary
AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.
Detailed description
AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, and special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body. AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress roles. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before. AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ... The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive processes are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation. AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, and SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations. AntiCov-220 is easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health. AntiCov-220 can be used alongside current standard treatment regimens prescribed by the World Health Organization.
Interventions
DRUGAntiCov-220
The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.
DRUGAntiCov-220 (placebo)
The daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time.
Sponsors
Nguyen Thi Trieu, MD
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
16 Years to 82 Years
Healthy volunteers
Yes
Inclusion criteria
* All patients with underlying medical conditions who have been taking medications for these conditions. * Patients with AIDS, HIV, HBV, HCV, and patients with co-infections. * The cancer patients are stable. * Patients with congenital or acquired immunodeficiency.
Exclusion criteria
* Unstable cancer patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1) | - 18 months | COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 * One case of Covid-19 infection with no severe change in a patient with HBeAg (+). * A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2) | - 18 months | COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 \_ No one has been infected with Covid-19. Of the 47 follow-up subjects in this group, 40 were vaccinated and 7 were unvaccinated. |
Countries
United States, Vietnam
Outcome results
None listed